Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | GABRP | O00591 | 3/20 | 0.48 |
| ▸ | GABRD | O14764 | 3/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.48 |
| ▸ | GABRE | P78334 | 3/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromazepam SCHEMBL43933 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29366892 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29521776 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL17225092 | 0.85 | ADRA1A (0.73) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL8414304 | 0.85 | ADRA1A (0.73) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7377690 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7374778 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7951942 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL14215423 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7477766 | 0.84 | ADRA1A (0.72) | ADRA1AGABRA1GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2026-03-05 | — | — | US | disclosed |
| US-12409137-B2 | Modification of plant messenger packs with charged lipids | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2025127612-A1 | CANINE PDL-1 ANTIBODY AND USE THEREOF | 주식회사 노드큐어 | 2025-06-19 | — | — | WO | disclosed |
| US-20250104836-A1 | DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION | POP TEST ABUSE DETERRENT TECH LLC (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025030724-A1 | CONSTRUCTION METHOD FOR AND USE OF RHIZOMA PINELLINAE PRAEPARATA DECOCTION PIECE, STANDARD DECOCTION AND FORMULA GRANULE CHARACTERISTIC SPECTRA | 四川新绿色药业科技发展有限公司 | 2025-02-13 | — | — | WO | disclosed |
| US-12205696-B2 | Drug device configured for wireless communication | POP TEST ABUSE DETERRENT TECHNOLOGY LLC (US) | 2025-01-21 | — | — | US | disclosed |
| CN-117054566-B | Standard decoction characteristic spectrum method and identification of rhizoma cyrtomii and rhizoma cyrtomii carbon decoction pieces, standard decoction and formula granules | 四川新绿色药业科技发展有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-114727959-B | Modification of plant messenger bags with charged lipids | 旗舰创业创新六公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-3538935-B1 | A PHOTONIC RESONANT MOTOR | QOPSYS S R L (IT) | 2024-09-18 | — | — | EP | disclosed |
| US-20240298649-A1 | MODIFICATION OF PLANT MESSENGER PACKS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-09-12 | — | — | US | disclosed |
| CN-115397977-A | Compositions and methods for producing glucose oxidation products | 索鲁根公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-110885392-B | Dual catalyst system for producing LLDPE copolymers having narrow molecular weight distribution and improved processability | 切弗朗菲利浦化学公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115315256-A | Methods of treating cancer with anti-TIGIT antagonist antibodies | 基因泰克公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-115175944-A | Degradation method | 卡特克塞尔科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220304930-A1 | MODIFICATION OF PLANT MESSENGER PACKS WITH CHARGED LIPIDS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-09-29 | — | — | US | disclosed |
| CN-115023226-A | Compound and use thereof | 福宏治疗公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
| EP-4017479-A1 | MODIFICATION OF PLANT MESSENGER PACKS WITH CHARGED LIPIDS | Flagship Pioneering Innovations VI, LLC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-112194406-B | HBSY-KL type temperature-inhibiting anti-cracking anticorrosion waterproof additive for concrete | 湖北省水利水电规划勘测设计院 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12205696-B2 | Drug device configured for wireless communication | CYP2D6, CYP2B6, PTGDR | GABRA2 516/4885ADRA1A 375/4885GABRA1 623/4885 |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | GABRA2 3429/4885ADRA1A 1771/4885GABRA1 3331/4885 |
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | CPT1A, CPT2, CNR2 | GABRA2 2023/4885ADRA1A 41/4885GABRA1 1875/4885 |
| US-20250104836-A1 | DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION | CYP2D6, CYP2B6, PTGDR | GABRA2 516/4885ADRA1A 375/4885GABRA1 623/4885 |
| US-20240298649-A1 | MODIFICATION OF PLANT MESSENGER PACKS | PHOSPHO1, OSGEP, USE1 | GABRA2 4434/4885ADRA1A 4119/4885GABRA1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.